Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Shutters who wrote (2236)	12/11/1998 12:21:00 PM
From: Tom Shutters	Respond to of 2836

"IL-2 improves response of HAART-treated patients" ..."They also found that subjects who received individualized IL-2 treatment were given only 58% of the amount of drug that subjects in the fixed-dose treatment group received, but still had comparable increases in CD4 cells."... ..."Dr. Hengge's group detected no opportunistic infections in the IL-2–treated group"... ..."Overall, the investigators conclude that the addition of IL-2 to HAART improves the immunologic and clinical profile for most patients, and individualized IL-2 therapy can improve effectiveness and tolerance."... ama-assn.org